Blueprint Medicines Co. (NASDAQ:BPMC) CEO Kate Haviland Sells 1,446 Shares

Blueprint Medicines Co. (NASDAQ:BPMC) CEO Kate Haviland sold 1,446 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the sale, the chief executive officer now directly owns 149,378 shares in the company, valued at approximately $16,467,430.72. This represents a 0.96 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Kate Haviland also recently made the following trade(s):

• On Friday, November 29th, Kate Haviland sold 2,353 shares of Blueprint Medicines stock. The shares were sold at an average price of $96.60, for a total transaction of $227,299.80.

Blueprint Medicines Trading Down 0.6 %

NASDAQ BPMC opened at $114.91 on Friday. Blueprint Medicines Co. has a one year low of $72.24 and a one year high of $121.90. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The firm has a market cap of $7.30 billion, a P/E ratio of -54.46 and a beta of 0.61. The stock’s 50-day moving average is $95.80 and its 200-day moving average is $95.33.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.08. The firm had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business’s quarterly revenue was up 126.5% on a year-over-year basis. During the same period last year, the company posted ($2.20) EPS. Sell-side analysts anticipate that Blueprint Medicines Co. will post -3.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Blueprint Medicines

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BPMC. Amalgamated Bank lifted its holdings in shares of Blueprint Medicines by 5.3% in the second quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock valued at $232,000 after purchasing an additional 109 shares in the last quarter. Pallas Capital Advisors LLC lifted its stake in Blueprint Medicines by 3.2% in the 3rd quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock valued at $523,000 after acquiring an additional 176 shares in the last quarter. Clarus Wealth Advisors lifted its stake in Blueprint Medicines by 8.6% in the 3rd quarter. Clarus Wealth Advisors now owns 2,590 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 206 shares in the last quarter. Mackenzie Financial Corp boosted its position in Blueprint Medicines by 5.2% during the 2nd quarter. Mackenzie Financial Corp now owns 4,885 shares of the biotechnology company’s stock worth $527,000 after acquiring an additional 243 shares during the last quarter. Finally, Franklin Resources Inc. grew its stake in shares of Blueprint Medicines by 0.7% during the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after acquiring an additional 265 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts have issued reports on BPMC shares. StockNews.com raised Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Stephens reiterated an “overweight” rating and issued a $140.00 price target on shares of Blueprint Medicines in a report on Thursday, January 2nd. HC Wainwright reissued a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, November 15th. JPMorgan Chase & Co. started coverage on shares of Blueprint Medicines in a research note on Thursday, November 14th. They issued an “overweight” rating and a $126.00 target price on the stock. Finally, UBS Group began coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 price target for the company. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $122.72.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.